Skip to main content

8 Result(s)

within Carsten Weishaupt Remove this filter

and

  1. Article

    Open Access

    A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

    Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is an oncolytic immunotherapy approved in Europe for the treatment of unresectable metastatic melanoma (stage IIIB–IVM1a). This study characterised real-worl...

    Alexander C. J. van Akkooi, Sebastian Haferkamp, Sophie Papa… in Advances in Therapy (2021)

    Download PDF (695 KB) View Article

  2. No Access

    Article

    De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma

    Radiotherapy (RT) has an established role in the curative treatment of indolent primary cutaneous B‑cell lymphoma (PCBCL). With the role of low-dose regimens such as 2 × 2 Gy being uncertain, we compared conve...

    Michael Oertel MD, Khaled Elsayad, Carsten Weishaupt… in Strahlentherapie und Onkologie (2020)

  3. No Access

    Article

    Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases

    PD-1 inhibition (PD-1i) is the standard of care in melanoma and other malignancies. In patients with bone metastases of solid tumors, the monoclonal antibody denosumab directed against RANKL is approved for th...

    Yenny Angela, Sebastian Haferkamp, Carsten Weishaupt… in Cancer Immunology, Immunotherapy (2019)

  4. Article

    Open Access

    Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey

    Talimogene laherparepvec is a first-in-class oncolytic immunotherapy for intratumoral injection with proven efficacy and tolerability in patients with unresectable early metastatic melanoma (stage IIIB–IVM1a) ...

    Peter Mohr, Sebastian Haferkamp, Andreas Pinter, Carsten Weishaupt… in Advances in Therapy (2019)

    Download PDF (1162 KB) View Article

  5. Article

    Open Access

    Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

    Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients.

    Markus Hecht, Friedegund Meier, Lisa Zimmer, Bülent Polat… in British Journal of Cancer (2018)

    Download PDF (747 KB) View Article

  6. No Access

    Article

    New tools for assessing the individual risk of metastasis in renal cell carcinoma

    Localized renal cell carcinoma (RCC) progresses to metastastic disease in 20–40 % after surgical resection. Affected patients might benefit from adjuvant treatment and have to be reliably identified for treatm...

    Edwin Herrmann, Carsten Weishaupt, Birgit Pöppelmann… in Clinical & Experimental Metastasis (2013)

  7. No Access

    Article

    Identification of cells initiating human melanomas

    Cancer stem cells have been isolated from a number of human tumours. The latest example is a subpopulation of human malignant melanoma initiating cells, identified by their expression of the chemoresistance me...

    Tobias Schatton, George F. Murphy, Natasha Y. Frank, Kazuhiro Yamaura… in Nature (2008)

  8. No Access

    Article

    Adhesion molecules in cutaneous immunity

    Skin serves a vital role, providing protection from the broad array of pathogens present in our environment. In addition to the passive barrier functions of the skin, mammals have evolved a robust and versatil...

    Robert C. Fuhlbrigge, Carsten Weishaupt in Seminars in Immunopathology (2007)